Westminster Health Forum

Improving access to medicine: pricing, regulation and implementing the Life Sciences Industrial Strategy

Morning, Thursday, 1st March 2018

Central London


Following the publication of the Life Sciences Industrial Strategy and the Government response to the Accelerated Access Review, delegates at this seminar will discuss the challenges and opportunities for improving access to medical treatments.

Planned sessions will focus on the recommendations in the response to the AAR, including aligning the work of executive agencies through an Accelerated Access Collaborative, encouraging local routes to market, improving NHS England’s commercial awareness through a new Strategic Commercial Unit - alongside addressing access in an early life sciences sector deal and delivery of a new pathway from April 2018.

Further sessions will address the development of medicines regulation in light of the UK vote to leave the European Union and the relocation of the European Medicines Agency; key issues in using patient data to gauge the effectiveness of treatment and widen access - as well as priorities for increased funding for research and development.

Keynote Speakers

Tim de Gavre

Country Head, Sandoz and Vice-Chair, British Generic Manufacturers Association

Angela McFarlane

Market Development Director, UK and Ireland, IQVIA


Baroness Morgan of Drefelin

Chair, National Cancer Research Institute and Chief Executive, Breast Cancer Now

Daniel Zeichner MP


Professor Zaheer-Ud-Din Babar

Professor, Medicines and Healthcare, Department of Pharmacy, University of Huddersfield

Dr Nick Scott-Ram

Director of Commercial Development, Oxford Academic Health Science Network

Meindert Boysen

Programme Director, Centre for Health Technology Evaluation, NICE

David Ramsden

Chief Executive, Cystic Fibrosis Trust

Professor Mike Hannay

Managing Director, East Midlands Academic Health Science Network and Chair, AHSN Network